BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29524167)

  • 1. TIMP3 Promoter Methylation Represents an Epigenetic Marker of BRCA1ness Breast Cancer Tumours.
    Maleva Kostovska I; Jakimovska M; Popovska-Jankovic K; Kubelka-Sabit K; Karagjozov M; Plaseska-Karanfilska D
    Pathol Oncol Res; 2018 Oct; 24(4):937-940. PubMed ID: 29524167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
    Murria Estal R; Palanca Suela S; de Juan Jiménez I; Alenda Gonzalez C; Egoavil Rojas C; García-Casado Z; López Guerrero JA; Juan Fita MJ; Sánchez Heras AB; Segura Huerta Á; Santaballa Bertrán A; Chirivella González I; Llop García M; Pérez Simó G; Barragán González E; Bolufer Gilabert P
    Fam Cancer; 2016 Apr; 15(2):193-200. PubMed ID: 26723934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
    Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
    BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    J Pathol; 2006 Jan; 208(1):100-7. PubMed ID: 16278815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
    Shakeri H; Fakhrjou A; Nikanfar A; Mohaddes-Ardebili SM
    Clin Lab; 2016 Dec; 62(12):2333-2337. PubMed ID: 28164568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    Severson TM; Wolf DM; Yau C; Peeters J; Wehkam D; Schouten PC; Chin SF; Majewski IJ; Michaut M; Bosma A; Pereira B; Bismeijer T; Wessels L; Caldas C; Bernards R; Simon IM; Glas AM; Linn S; van 't Veer L
    Breast Cancer Res; 2017 Aug; 19(1):99. PubMed ID: 28851423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
    Daniels SL; Burghel GJ; Chambers P; Al-Baba S; Connley DD; Brock IW; Cramp HE; Dotsenko O; Wilks O; Wyld L; Cross SS; Cox A
    PLoS One; 2016; 11(7):e0160174. PubMed ID: 27463681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
    BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of aberrant DNA methylation with clinicopathological features in breast cancer.
    Tserga A; Michalopoulos NV; Levidou G; Korkolopoulou P; Zografos G; Patsouris E; Saetta AA
    Oncol Rep; 2012 May; 27(5):1630-8. PubMed ID: 22159596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
    Lips EH; Laddach N; Savola SP; Vollebergh MA; Oonk AM; Imholz AL; Wessels LF; Wesseling J; Nederlof PM; Rodenhuis S
    Breast Cancer Res; 2011 Oct; 13(5):R107. PubMed ID: 22032731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
    Branham MT; Campoy E; Laurito S; Branham R; Urrutia G; Orozco J; Gago F; Urrutia R; Roqué M
    Breast Cancer Res Treat; 2016 Jan; 155(1):13-23. PubMed ID: 26610810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients.
    Debouki-Joudi S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
    Cancer Biomark; 2017; 18(2):133-141. PubMed ID: 27983523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypomethylation of TIMP3 is associated with pre-eclampsia in a Chinese population.
    Xiang Y; Zhang X; Li Q; Xu J; Zhou X; Wang T; Xing Q; Liu Y; Wang L; He L; Zhao X
    Mol Hum Reprod; 2013 Mar; 19(3):153-9. PubMed ID: 23172037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
    PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.